US equities
|
MU
$896.07
▼-0.98%
SPCX
$147.79
▼-0.11%
NVDA
$216.47
▼-0.29%
AAPL
$339.50
▼-1.00%
TSLA
$373.71
▲+1.54%
META
$694.25
▼-1.59%
AMZN
$262.63
▲+0.07%
SNDK
$1,365.38
▼-0.42%
MU
$896.07
▼-0.98%
SPCX
$147.79
▼-0.11%
NVDA
$216.47
▼-0.29%
AAPL
$339.50
▼-1.00%
TSLA
$373.71
▲+1.54%
META
$694.25
▼-1.59%
AMZN
$262.63
▲+0.07%
SNDK
$1,365.38
▼-0.42%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by BostonGene
< Previous
1
2
Next >
BostonGene and Medical University of South Carolina Announce Strategic Collaboration to Advance CAR-T Therapy Insights for Lymphoma and Leukemia
October 20, 2026
From
BostonGene
Via
Business Wire
BostonGene Showcases Biologically Grounded AI at ESMO Congress 2026 to Advance Drug Development and Precision Clinical Decision-Making
October 19, 2026
From
BostonGene
Via
Business Wire
BostonGene and Kyoto University Establish Strategic Partnership to Advance Biomarker Discovery for Combination Immunotherapy
July 22, 2026
From
BostonGene
Via
Business Wire
BostonGene Named “Overall AI-based Analytics Company of the Year” in 2026 AI Breakthrough Awards Program
July 07, 2026
From
BostonGene
Via
Business Wire
BostonGene to Feature Next-Generation AI Foundation Models for Precision Immuno-Oncology at the 22nd Annual RadMed Symposium
June 10, 2026
From
BostonGene
Via
Business Wire
BostonGene Receives Diamond Pinnacle Award for AI-Driven Decision-Making in Oncology Drug Prediction
June 09, 2026
From
BostonGene
Via
Business Wire
BostonGene to Present High-Impact AI Models and Biomarker-Driven Frameworks at EHA2026 Congress
June 08, 2026
From
BostonGene
Via
Business Wire
BostonGene to Demonstrate Power of AI Models in Tumor and Immune Biology at the 2026 ASCO® Annual Meeting
May 28, 2026
From
BostonGene
Via
Business Wire
BostonGene and ImmunoGenesis Announce Strategic Partnership to Overcome Immunotherapy Resistance
April 14, 2026
From
BostonGene
Via
Business Wire
BostonGene to Present 13 Abstracts at the American Association for Cancer Research Annual Meeting 2026 Showcasing AI-Platform for Drug Development
April 09, 2026
From
BostonGene
Via
Business Wire
BostonGene to Highlight the Role of AI Foundation Models in Optimizing Cancer Immunotherapy at Precision Medicine World Conference 2026
March 02, 2026
From
BostonGene
Via
Business Wire
BostonGene Named “Overall Immunology Company of the Year” by BioTech Breakthrough for Its AI-Driven Platform That Transforms Immuno-Oncology Drug Development Through Advanced Biomarker Discovery, Real-Time Monitoring, and Precision Patient Selection
December 16, 2025
From
BostonGene
Via
Business Wire
BostonGene to Present Seven Studies Unveiling Novel AI-Driven Breast Cancer Breakthroughs at SABCS 2025
December 08, 2025
From
BostonGene
Via
Business Wire
BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition
November 25, 2025
From
BostonGene
Via
Business Wire
BostonGene and Kyoto University Partner to Accelerate Precision Drug Development
November 12, 2025
From
BostonGene
Via
Business Wire
BostonGene to Present Omnimodal Foundation AI for Cancer and the Immune System at SITC 2025 Annual Meeting
October 28, 2025
From
BostonGene
Via
Business Wire
BostonGene to Highlight Omnimodal AI Innovations for Precision Oncology at the 21st Annual Precision Oncology & RadMed Symposium
October 23, 2025
From
BostonGene
Via
Business Wire
BostonGene Honored with Five 2025 Stevie® Awards for Technology Excellence
October 21, 2025
From
BostonGene
Via
Business Wire
BostonGene Showcases AI-Powered Multimodal Analytics at ESMO Congress 2025 to Advance Cancer Research and Drug Development
October 14, 2025
From
BostonGene
Via
Business Wire
BostonGene Named Platinum Winner for AI Research Innovation at 2025 Pinnacle Awards
September 17, 2025
From
BostonGene
Via
Business Wire
BostonGene to Participate in the 2025 IASLC World Conference on Lung Cancer
August 26, 2025
From
BostonGene
Via
Business Wire
BostonGene Publishes Landmark Study Providing Clinical and Analytical Validation for Its Multimodal RNA and DNA Assay
August 12, 2025
From
BostonGene
Via
Business Wire
BostonGene Named “AI-based Drug Discovery Solution of the Year” in 2025 AI Breakthrough Awards Program
August 07, 2025
From
BostonGene
Via
Business Wire
BostonGene Announces Collaboration with SWOG Cancer Research Network to Drive Personalized Approaches
July 08, 2025
From
BostonGene
Via
Business Wire
BostonGene to Present AI-Powered Solutions Advancing Patient-Centric Drug Development at The Festival of Genomics & Biodata Boston 2025
June 18, 2025
From
BostonGene
Via
Business Wire
BostonGene’s Multiomic AI Platform Uncovers Therapeutic Targets in Invasive Lobular Carcinoma, Wins GRASP Advocate Choice Award at ASCO 2025
June 09, 2025
From
BostonGene
Via
Business Wire
BostonGene Announces Participation at the American Association for Cancer Research Annual Meeting 2025
April 21, 2025
From
BostonGene
Via
Business Wire
BostonGene Appoints Dr. Ferran Prat as Chief Commercial Officer
April 08, 2025
From
BostonGene
Via
Business Wire
BostonGene to Participate in the 114th Annual Meeting of the United States and Canadian Academy of Pathology
March 24, 2025
From
BostonGene
Via
Business Wire
BostonGene Named a Fierce Life Sciences Innovation Awards Winner in the AI Innovation Category
March 13, 2025
From
BostonGene
Via
Business Wire
< Previous
1
2
Next >
